A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™
Launched by UNIVERSITY OF OXFORD · Mar 12, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new malaria vaccine called R21/Matrix-M™ to see how safe it is and how well it can help the body build protection against malaria. The trial is focused on healthy adults aged 18 to 50 who have never had malaria before and are willing to follow the study's requirements. Participants should not have any history of malaria, should not be pregnant, and need to agree to use effective contraception if they can become pregnant.
If you join this study, you will receive a series of vaccine doses and be monitored closely for any side effects or reactions. The main goal is to ensure that the vaccine is safe to use and to see how well it works in creating an immune response. It's important to know that you won't be able to donate blood during the trial, and you’ll need to provide written consent to participate. This research is a key step in developing better ways to prevent malaria, a serious disease that affects many people worldwide.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy adult aged 18 to 50 years.
- • Able and willing (in the Investigator's opinion) to comply with all study requirements.
- • Participants of childbearing potential only: must practice continuous effective contraception until the last study visit.
- • Agreement to refrain from blood donation for the duration of the study.
- • Able and willing to provide written informed consent to participate in the trial.
- Exclusion Criteria:
- • History of clinical malaria (any species) or previous participation in any malaria vaccine trial or controlled human malaria infection trial.
- • Travel to a clearly malaria endemic locality during the study period or within the preceding six months, as per the CDC website: https://www.cdc.gov/malaria/travelers/country_table/a.html
- • Participation in another research study involving receipt of an investigational medicinal product (IMP) in the 30 days preceding enrolment or 5 half-lives of the investigational medicinal product, whichever is longer, or planned participation during the study period.
- • Prior receipt of an IMP likely to impact interpretation of the trial data, as assessed by the Investigator.
- • Receipt of any vaccine within 30 days of a study vaccine, with the exception of COVID-19 vaccination.
- • Receipt of oral or systemic immunosuppressant medication for more than 14 days in the six months preceding enrolment.
- • Receipt of immunoglobulins or blood products (e.g. blood transfusion) in the three months preceding enrolment.
- • History of anaphylaxis to vaccination, or allergy likely to be exacerbated by any component of the vaccine or study procedures, including allergy to lidocaine
- • Pregnancy, lactation or intention to become pregnant during the study.
- • Clinically significant history of chronic disease, including cancer (except basal cell carcinoma or cervical carcinoma in situ), immunodeficiency (including HIV), autoimmune conditions (except mild psoriasis, well-controlled autoimmune thyroid disease, vitiligo or stable coeliac disease), psychiatric disorder, drug or alcohol abuse
- • Positive Hepatitis B surface antigen (HBsAg), HIV antibodies or Hepatitis C (HCV) antibodies (except previous HCV vaccine study participants)
- • HEMStop score \> or = to 2(30) with abnormal coagulation screen or clinical concern regarding bleeding risk.
- • Use of medications that increase the risk of bleeding, as assessed by the clinician, including: warfarin, oral antithrombin agents (e.g. Apixaban), low molecular weight heparin
- • Any clinically significant abnormality of screening examination, blood or urine tests
- • Any other significant disease, disorder, or finding, which, in the opinion of the Investigator, may put the volunteer at risk, affect the volunteer's ability to participate in the study or impair interpretation of the study data
- • Participants unable to be closely followed for social, geographic or psychological reasons.
- • Investigator inability to corroborate a participant's medical history via access to NHS electronic records and/or their GP.
About University Of Oxford
The University of Oxford, a prestigious institution renowned for its excellence in research and education, serves as a leading clinical trial sponsor dedicated to advancing medical science and improving patient care. With a rich history of innovation and a multidisciplinary approach, the university leverages its extensive expertise in various fields, including medicine, public health, and biomedical research, to conduct rigorous clinical trials. Collaborating with healthcare professionals, industry partners, and regulatory bodies, the University of Oxford aims to translate groundbreaking research findings into effective therapies and interventions, contributing to the global effort of enhancing health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bristol, , United Kingdom
Oxford, Oxfordshire, United Kingdom
Patients applied
Trial Officials
Susanne Hodgson, DPhil FRCP
Principal Investigator
Center for Clinical Vaccinology and Tropical Medicine, University of Oxford
Rajeka Lazarus, DPhil FRCP
Principal Investigator
University Hospitals Bristol and Weston Foundation Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported